A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
NCT ID: NCT00502710
Last Updated: 2016-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
289 participants
INTERVENTIONAL
2007-07-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
NCT00111631
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
NCT00800176
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
NCT00525330
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
NCT02164266
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RO4876904 1
Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
RO4876904
Escalating doses, at a starting dose of 12.5mg po daily.
RO4876904 2
Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
RO4876904
Escalating doses, at a starting dose of 12.5mg po daily.
RO4876904 3
Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
RO4876904
Escalating doses, at a starting dose of 12.5mg po daily.
RO4876904 4
Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
RO4876904
Escalating doses, at a starting dose of 12.5mg po daily.
Placebo
Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
Placebo
Placebo po daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo po daily.
RO4876904
Escalating doses, at a starting dose of 12.5mg po daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes diagnosed \>= 1 month before screening;
* drug-naive, or pretreated with maximum tolerated dose (MTD) of metformin;
* BMI 25-45kg/m2.
Exclusion Criteria
* any anti-hyperglycemic medication other than metformin, or weight-lowering drug, during last 3 months.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hot Springs, Arkansas, United States
Concord, California, United States
Los Angeles, California, United States
Chicago, Illinois, United States
Avon, Indiana, United States
Indianapolis, Indiana, United States
Oxon Hill, Maryland, United States
Troy, Michigan, United States
Omaha, Nebraska, United States
Binghamton, New York, United States
Charlotte, North Carolina, United States
Beaver, Pennsylvania, United States
Adelaide, , Australia
Canberra, , Australia
St Leonards, , Australia
São Paulo, , Brazil
São Paulo, , Brazil
Guatemala City, , Guatemala
Hong Kong, , Hong Kong
Aguascalientes, , Mexico
Chihuahua City, , Mexico
Guadalajara, , Mexico
Guadalajara, , Mexico
Mexico City, , Mexico
Pachuca, , Mexico
Tampico, , Mexico
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saratov, , Russia
Yaroslavl, , Russia
Yaroslavl, , Russia
Alzira, , Spain
Bacarot Alicant, , Spain
Badalona, , Spain
Barcelona, , Spain
Ferrol, , Spain
Bath, , United Kingdom
Frome, , United Kingdom
Glasgow, , United Kingdom
Liverpool, , United Kingdom
Motherwell, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BC20779
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.